Myasthenia gravis (MG) is an autoimmune disorder characterized by antibodies that disrupt communication at the neuromuscular junction, causing muscle weakness and fatigue. This condition often manifests with variable muscle strength that deteriorates with exertion but recovers with rest and may start with ocular symptoms in up to 85% of cases. While it may only affect ocular muscles in some, others may experience more extensive symptoms, including weakness in bulbar and limb muscles, influenced by environmental and physiological factors.

Treatment for MG is customized according to each patient’s specific autoimmune characteristics and symptoms, utilizing a range of options from anticholinesterase inhibitors like pyridostigmine for symptom management to immunosuppressants such as prednisone for sustained control. Advanced treatment strategies include plasmapheresis, intravenous immunoglobulins, and monoclonal antibodies that target specific immune pathways, alongside thymectomy for those with thymic anomalies. Effective management of MG requires continuous assessment and adaptation of therapies to address the variable nature of the disease and improve patient outcomes.

Reference: Shah A. Myasthenia Gravis. Medscape. Updated December 05, 2023. Accessed April 30, 2024. https://emedicine.medscape.com/article/1171206-overview?form=fpf